573.91
-5.62 (-0.97%)
| 前收盘价格 | 579.53 |
| 收盘价格 | 582.09 |
| 成交量 | 576,503 |
| 平均成交量 (3个月) | 1,170,093 |
| 市值 | 60,826,996,736 |
| 市盈率 (P/E TTM) | 14.46 |
| 预期市盈率 (P/E Forward) | 15.92 |
| 价格/销量 (P/S) | 4.59 |
| 股市价格/股市净资产 (P/B) | 2.05 |
| 52周波幅 | |
| 利润日期 | 30 Oct 2025 |
| 股息率 (DY TTM) | 0.31% |
| 营业毛利率 | 31.94% |
| 营业利益率 (TTM) | 19.94% |
| 稀释每股收益 (EPS TTM) | 39.36 |
| 季度收入增长率 (YOY) | -3.70% |
| 季度盈利增长率 (YOY) | 12.00% |
| 总债务/股东权益 (D/E MRQ) | 9.20% |
| 流动比率 (MRQ) | 4.93 |
| 营业现金流 (OCF TTM) | 3.95 B |
| 杠杆自由现金流 (LFCF TTM) | 2.08 B |
| 资产报酬率 (ROA TTM) | 6.91% |
| 股东权益报酬率 (ROE TTM) | 15.96% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | Regeneron Pharmaceuticals, Inc. | 看涨 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | -1.0 |
| 技术平均移动指标 | 1.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 1.63 |
|
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia). |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Mid Value |
| 内部持股比例 | 1.89% |
| 机构持股比例 | 91.98% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 850.00 (Canaccord Genuity, 48.11%) | 购买 |
| 中 | 728.00 (26.85%) | |
| 低 | 580.00 (Wells Fargo, 1.06%) | 保留 |
| 平均值 | 718.70 (25.23%) | |
| 总计 | 7 购买, 3 保留 | |
| 平均价格@调整类型 | 547.09 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Truist Securities | 11 Aug 2025 | 812.00 (41.49%) | 购买 | 545.94 |
| BMO Capital | 04 Aug 2025 | 640.00 (11.52%) | 购买 | 571.54 |
| 02 Jun 2025 | 600.00 (4.55%) | 购买 | 490.81 | |
| Guggenheim | 04 Aug 2025 | 815.00 (42.01%) | 购买 | 571.54 |
| Morgan Stanley | 04 Aug 2025 | 761.00 (32.60%) | 购买 | 571.54 |
| 10 Jul 2025 | 754.00 (31.38%) | 购买 | 559.76 | |
| RBC Capital | 04 Aug 2025 | 695.00 (21.10%) | 保留 | 571.54 |
| 27 May 2025 | 943.00 (64.31%) | 购买 | 603.26 | |
| Canaccord Genuity | 23 Jul 2025 | 850.00 (48.11%) | 购买 | 572.39 |
| UBS | 11 Jul 2025 | 584.00 (1.76%) | 保留 | 567.74 |
| 05 Jun 2025 | 560.00 (-2.42%) | 保留 | 483.07 | |
| JP Morgan | 09 Jun 2025 | 800.00 (39.39%) | 购买 | 517.60 |
| Citigroup | 02 Jun 2025 | 650.00 (13.26%) | 购买 | 490.81 |
| Wells Fargo | 30 May 2025 | 580.00 (1.06%) | 保留 | 490.28 |
| 显示更多 | ||||
该时间范围内无数据。
| 股息率 (DY TTM) | 0.31% |
| 股息支付比率 | 2.24% |
| 预计下次股息支付 | Mar 2026 |
| 除息日 | 公告日期 | 支付日期 | 详情 |
|---|---|---|---|
| 18 Aug 2025 | - | 03 Sep 2025 | 0.88 现金 |
| 20 May 2025 | - | 06 Jun 2025 | 0.88 现金 |
| 20 Feb 2025 | - | 20 Mar 2025 | 0.88 现金 |
每年股息收益率
| 年份 | 每年总股息 ($) | 频率/年份 | 收益率 % |
|---|---|---|---|
| 2025 | 2.64 | 3 | 0.46 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合